Does the media prefer AMRX or VTRS?

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Amneal Pharmaceuticals and 4 mentions for Viatris. Viatris' average media sentiment score of 0.54 beat Amneal Pharmaceuticals' score of 0.42 indicating that Viatris is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMRX or GMAB?

In the previous week, Genmab A/S had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Genmab A/S and 5 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat Genmab A/S's score of -0.04 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ASND or AMRX?

In the previous week, Ascendis Pharma A/S had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 5 mentions for Amneal Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.73 beat Amneal Pharmaceuticals' score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AMRX or BBIO?

In the previous week, BridgeBio Pharma had 8 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 5 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat BridgeBio Pharma's score of 0.26 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor AXSM or AMRX?

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 5 articles in the media. Axsome Therapeutics' average media sentiment score of 0.50 beat Amneal Pharmaceuticals' score of 0.42 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Amneal Pharmaceuticals 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Amneal Pharmaceuticals (AMRX) Competitors

$17.31 +0.02 (+0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$17.60 +0.29 (+1.68%)

As of 06:23 PM Eastern

Compare

AMRX vs. VTRS, GMAB, ASND, BBIO, and AXSM

Should you buy Amneal Pharmaceuticals stock or one of its competitors? MarketBeat compares Amneal Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Amneal Pharmaceuticals include Viatris (VTRS), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Axsome Therapeutics (AXSM). These companies are all part of the "pharmaceutical products" industry.

How does Amneal Pharmaceuticals compare to Viatris?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk, institutional ownership and media sentiment.

In the previous week, Amneal Pharmaceuticals had 1 more articles in the media than Viatris. MarketBeat recorded 5 mentions for Amneal Pharmaceuticals and 4 mentions for Viatris. Viatris' average media sentiment score of 0.54 beat Amneal Pharmaceuticals' score of 0.42 indicating that Viatris is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Viatris	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals has a net margin of 4.01% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Viatris	-2.04%	19.04%	7.62%

Amneal Pharmaceuticals currently has a consensus target price of $15.80, suggesting a potential downside of 8.72%. Viatris has a consensus target price of $17.50, suggesting a potential upside of 10.20%. Given Viatris' higher possible upside, analysts plainly believe Viatris is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Comparatively, 0.3% of Viatris shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has higher earnings, but lower revenue than Viatris. Viatris is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.83	$72.06M	$0.38	45.55
Viatris	$14.56B	1.27	-$3.51B	-$0.26	N/A

Amneal Pharmaceuticals has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Viatris has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Viatris on 10 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Genmab A/S?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Genmab A/S has a net margin of 21.05% compared to Amneal Pharmaceuticals' net margin of 4.01%. Genmab A/S's return on equity of 15.34% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Genmab A/S	21.05%	15.34%	8.94%

Amneal Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 1.5% of Genmab A/S shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genmab A/S has higher revenue and earnings than Amneal Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.83	$72.06M	$0.38	45.55
Genmab A/S	$3.90B	4.39	$963M	$1.32	20.81

In the previous week, Genmab A/S had 3 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 8 mentions for Genmab A/S and 5 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat Genmab A/S's score of -0.04 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Amneal Pharmaceuticals presently has a consensus price target of $15.80, indicating a potential downside of 8.72%. Genmab A/S has a consensus price target of $37.93, indicating a potential upside of 38.07%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Genmab A/S beats Amneal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Amneal Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	20.43	-$258M	$8.67	30.76
Amneal Pharmaceuticals	$3.02B	1.83	$72.06M	$0.38	45.55

Ascendis Pharma A/S has a net margin of 57.87% compared to Amneal Pharmaceuticals' net margin of 4.01%. Ascendis Pharma A/S's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S presently has a consensus price target of $295.39, indicating a potential upside of 10.75%. Amneal Pharmaceuticals has a consensus price target of $15.80, indicating a potential downside of 8.72%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, analysts clearly believe Ascendis Pharma A/S is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Ascendis Pharma A/S had 9 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 14 mentions for Ascendis Pharma A/S and 5 mentions for Amneal Pharmaceuticals. Ascendis Pharma A/S's average media sentiment score of 0.73 beat Amneal Pharmaceuticals' score of 0.42 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	4 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a beta of 0.39, indicating that its share price is 61% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Summary

Ascendis Pharma A/S beats Amneal Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Amneal Pharmaceuticals (NASDAQ:AMRX) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership, profitability and media sentiment.

Amneal Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.98, suggesting that its stock price is 2% less volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.83	$72.06M	$0.38	45.55
BridgeBio Pharma	$502.08M	29.05	-$724.93M	-$3.74	N/A

In the previous week, BridgeBio Pharma had 8 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 13 mentions for BridgeBio Pharma and 5 mentions for Amneal Pharmaceuticals. Amneal Pharmaceuticals' average media sentiment score of 0.42 beat BridgeBio Pharma's score of 0.26 indicating that Amneal Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 4.01% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
BridgeBio Pharma	-124.42%	N/A	-65.81%

Amneal Pharmaceuticals presently has a consensus price target of $15.80, indicating a potential downside of 8.72%. BridgeBio Pharma has a consensus price target of $92.90, indicating a potential upside of 24.73%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, analysts plainly believe BridgeBio Pharma is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Amneal Pharmaceuticals beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Axsome Therapeutics and Axsome Therapeutics both had 5 articles in the media. Axsome Therapeutics' average media sentiment score of 0.50 beat Amneal Pharmaceuticals' score of 0.42 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Axsome Therapeutics has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market.

Amneal Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	19.73	-$183.17M	-$3.73	N/A
Amneal Pharmaceuticals	$3.02B	1.83	$72.06M	$0.38	45.55

81.5% of Axsome Therapeutics shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Axsome Therapeutics presently has a consensus target price of $258.95, indicating a potential upside of 5.79%. Amneal Pharmaceuticals has a consensus target price of $15.80, indicating a potential downside of 8.72%. Given Axsome Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Axsome Therapeutics is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Amneal Pharmaceuticals has a net margin of 4.01% compared to Axsome Therapeutics' net margin of -26.59%. Axsome Therapeutics' return on equity of -267.16% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%

Summary

Axsome Therapeutics beats Amneal Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Amneal Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AMRX vs. The Competition

Export

Metric	Amneal Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.52B	$3.04B	$6.76B	$12.60B
Dividend Yield	N/A	1.87%	2.66%	6.21%
P/E Ratio	45.55	19.29	27.33	24.88
Price / Sales	1.83	495.13	561.84	115.98
Price / Cash	11.03	56.85	29.14	36.96
Price / Book	-75.26	4.27	11.01	6.56
Net Income	$72.06M	$64.45M	$3.57B	$336.70M
7 Day Performance	3.90%	3.18%	2.56%	3.31%
1 Month Performance	31.44%	3.80%	0.89%	1.68%
1 Year Performance	113.97%	34.43%	36.84%	31.96%

Amneal Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AMRX Amneal Pharmaceuticals	2.0614 of 5 stars	$17.31 +0.1%	$15.80 -8.7%	+112.7%	$5.52B	$3.02B	45.55	8,500	Analyst Downgrade
VTRS Viatris	2.8724 of 5 stars	$15.78 +2.6%	$17.50 +10.9%	+80.1%	$18.36B	$14.30B	N/A	30,000
GMAB Genmab A/S	4.6781 of 5 stars	$26.08 +1.8%	$37.93 +45.4%	+26.9%	$16.27B	$3.72B	19.77	3,029	News Coverage Gap Up
ASND Ascendis Pharma A/S	4.255 of 5 stars	$234.18 +2.7%	$295.39 +26.1%	+53.1%	$14.60B	$865.78M	27.00	1,189
BBIO BridgeBio Pharma	3.1879 of 5 stars	$69.38 +0.7%	$91.05 +31.2%	+60.5%	$13.59B	$502.08M	N/A	400

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AMRX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Amneal Pharmaceuticals compare to Viatris?

Summary

How does Amneal Pharmaceuticals compare to Genmab A/S?

Summary

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Summary

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Summary

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amneal Pharmaceuticals (AMRX) Competitors

AMRX vs. VTRS, GMAB, ASND, BBIO, and AXSM

How does Amneal Pharmaceuticals compare to Viatris?

Does the media prefer AMRX or VTRS?

Is AMRX or VTRS more profitable?

Do analysts rate AMRX or VTRS?

Do institutionals & insiders hold more shares of AMRX or VTRS?

Which has higher earnings & valuation, AMRX or VTRS?

Which has more risk & volatility, AMRX or VTRS?

Summary

How does Amneal Pharmaceuticals compare to Genmab A/S?

Is AMRX or GMAB more profitable?

Which has more risk & volatility, AMRX or GMAB?

Do institutionals & insiders believe in AMRX or GMAB?

Which has preferable earnings & valuation, AMRX or GMAB?

Does the media refer more to AMRX or GMAB?

Do analysts rate AMRX or GMAB?

Summary

How does Amneal Pharmaceuticals compare to Ascendis Pharma A/S?

Which has preferable valuation & earnings, ASND or AMRX?

Is ASND or AMRX more profitable?

Do institutionals & insiders believe in ASND or AMRX?

Do analysts recommend ASND or AMRX?

Does the media refer more to ASND or AMRX?

Which has more volatility and risk, ASND or AMRX?

Summary

How does Amneal Pharmaceuticals compare to BridgeBio Pharma?

Which has more volatility & risk, AMRX or BBIO?

Which has better valuation and earnings, AMRX or BBIO?

Does the media refer more to AMRX or BBIO?

Do insiders and institutionals believe in AMRX or BBIO?

Is AMRX or BBIO more profitable?

Do analysts recommend AMRX or BBIO?

Summary

How does Amneal Pharmaceuticals compare to Axsome Therapeutics?

Does the media favor AXSM or AMRX?

Which has more risk and volatility, AXSM or AMRX?

Which has preferable valuation and earnings, AXSM or AMRX?

Do insiders and institutionals believe in AXSM or AMRX?

Do analysts rate AXSM or AMRX?

Is AXSM or AMRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMRX vs. The Competition

Amneal Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools